TTY Biopharm Co (ROCO:4105) Retained Earnings : NT$2,191 Mil (As of Dec. 2024)

View and export this data going back to 2001. Start your Free Trial

What is TTY Biopharm Co Retained Earnings?

Retained earnings is the accumulated portion of net income that is not distributed to shareholders. TTY Biopharm Co's retained earnings for the quarter that ended in Dec. 2024 was NT$2,191 Mil.

TTY Biopharm Co's quarterly retained earnings increased from Jun. 2024 (NT$1,157 Mil) to Sep. 2024 (NT$1,647 Mil) and increased from Sep. 2024 (NT$1,647 Mil) to Dec. 2024 (NT$2,191 Mil).

TTY Biopharm Co's annual retained earnings increased from Dec. 2022 (NT$1,448 Mil) to Dec. 2023 (NT$1,595 Mil) and increased from Dec. 2023 (NT$1,595 Mil) to Dec. 2024 (NT$2,191 Mil).

TTY Biopharm Co Retained Earnings Historical Data

The historical data trend for TTY Biopharm Co's Retained Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

TTY Biopharm Co Retained Earnings Chart

TTY Biopharm Co Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Retained Earnings

Get a 7-Day Free Trial

1,555.02

1,235.22

1,447.52

1,594.71

2,190.64

TTY Biopharm Co Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Retained Earnings	Get a 7-Day Free Trial															1,594.71	1,005.21	1,156.63	1,646.84	2,190.64

TTY Biopharm Co Retained Earnings Calculation

Retained Earnings is the accumulated portion of net income that is not distributed to shareholders. Because the net income was not distributed to shareholders, shareholders' equity is increased by the same amount.

Of course, if a company loses, it is called retained losses, or accumulated losses.

TTY Biopharm Co (ROCO:4105) Retained Earnings Explanation

Historically profitable companies sometimes have negative retained earnings. This is because they have cumulatively paid out more to shareholders than they reported in profits.

For example, in 2011, Microsoft had negative retained earnings. This does not mean the company lost more money than it made over the years. It just means it paid out more money than it earned.

If a company has negative retained earnings, investors should check the 10-year financial results. They should not assume that negative retained earnings prove a company has generally lost money in the past.

Of course, many companies with negative retained earnings have indeed lost money in the past.

Retained Earnings: Warren Buffett's Secret.

One of the most important indicators of durable competitive advantage. Net earnings can be paid out as dividends, used to buy back shares or retained for growth.

If the company loses more than it has accumulated, retained earnings is negative.

If a company isn't adding to its retained earnings, it isn't growing its net worth.

Rate of growth of retained earnings is good indicator whether it's benefiting from a competitive advantage.

Microsoft is negative because it chose to buyback stock and pay dividends.

The more earnings retained, the faster it grows and increases growth rate for future earnings.

TTY Biopharm Co Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » TTY Biopharm Co Ltd (ROCO:4105) » Definitions » Retained Earnings

Comparable Companies

Traded in Other Exchanges

N/A

Address

No. 3-1, Park Street, 3rd Floor, Nangang District, Taipei, TWN, 11503

Website

https://www.tty.com.tw

TTY Biopharm Co Ltd is engaged in the manufacturing and marketing of pharmaceuticals and chemical drugs. The company's operating segments includes Oncology Business unit, Health Care Business unit, Intensive Care Business Unit, Healthcare Business Unit, Export and CDMO Business unit segment. It generates maximum revenue from the Oncology segment. Geographically, it derives a majority of revenue from Taiwan and also has a presence in European and Other Countries. Some of its products include Algitab, Alginos, Sulfin, Metacin, Cepiro, Brosym, Colimycin, Cubicin, and others.

TTY Biopharm Co Headlines

No Headlines